Skip to main content

14-12-2019 | Breast cancer | Video

SABCS 2019 | Oral paclitaxel offers an option beyond IV treatment in metastatic breast cancer

Gerardo Umanzor discusses phase 3 findings showing improved survival and reduced neuropathy with orally administered versus intravenous paclitaxel in patients with metastatic breast cancer (3:12).

Funding for independent interviews at SABCS 2019 was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

See the research in context now

with trial summaries, expert opinion and congress coverage

Image Credits